Mary M. Zutter

Vice President for Integrative Diagnostics; Louise B. McGavock Professor of Pathology, Microbiology & ImmunologyDirector, Host-Tumor Interaction Program, Vanderbilt Ingram Cancer CenterNashville, TN
Mary Zutter

Bio: Dr. Zutter is a physician-scientist with clinical expertise in Pathology, Molecular Pathology and Hematopathology. She has combined her clinical efforts with a research portfolio focused on the molecular basis of cell-matrix interactions and the mechanisms by which these interactions influence cancer progression and metastasis. Building on her expertise in host-tumor research, she is active within the leadership of the Vanderbilt Ingram Cancer Center (VICC) and serves as the co-leader of the Host Tumor Interaction Program in VICC.

Dr. Zutter graduated from Tulane University Medical School and completed her pathology residency and hematopathology fellowship training at the University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center. She joined the Department of Pathology faculty at Washington University School of Medicine and served on the faculty for 15 years, before joining Vanderbilt University School of Medicine in 2003.

In July 2011, Dr. Zutter assumed the role of Vice President for Integrative Diagnostics. Her goal in this position is to enhance the activities of Vanderbilt University Medical Center in emerging integrative diagnostics at the leading edge of personalized medicine. This role integrates efforts across departments, centers, and disciplines to build the “best in class” personalized/precision medicine at Vanderbilt. Dr. Zutter’s team envisioned, developed and implemented an evidenced-based decision support system for oncologists within Vanderbilt Medical Center. The Diagnostic Management Team (DMT) serves as an exciting proof-of-concept that operationalizing real-time collaboration between oncologists and pathologists can improve diagnostic value and has been important in growing Vanderbilt’s position as a leader in precision medicine. She has led many of the genomics initiatives around cancer molecular testing and collaborative efforts to share data. Future efforts include developing a strategic plan for expansion of this precision medicine initiative across the Vanderbilt Health Affiliated Network.